Poxel Presents Promising Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting

SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), today announced that poster presentations for PXL770 and PXL065
(formerly DRX-065; acquired from DeuteRx LLC) showing promising data for
the treatment of NASH were made on November 10-11, 2018, at the American
Association for the Study of Liver Diseases (AASLD) meeting in San
Francisco, California.

In the first poster presentation, PXL770 was shown to have a beneficial
effect on the two key pathways involved in non-alcoholic fatty liver
disease (NAFLD), the lipolysis in the adipose tissue (AT) and de novo
lipogenesis in the liver, through direct activation of adenosine
monophosphate-activated protein kinase (AMPK) in a diet-induced obesity
non-alcoholic steatohepatitis (DIO-NASH) model. NAFLD is characterized
by hepatic lipid accumulation resulting primarily from AT lipolysis
(70%), and de novo lipogenesis (20%), highlighting the key role
of AT in the development of NAFLD.

"AMPK is a key target acting on steatosis, inflammation and hepatic
fibrogenesis,a?? said Sophie Bozec, PhD, Senior Vice President, Research
and Development Pharmacology at Poxel. "Supported by positive
preclinical mechanistic and efficacy results in a DIO-NASH model, we
believe that PXL770 is uniquely positioned to treat the underlying root
causes of NASH, including liver steatosis, inflammation and fibrosis,
which are driven by the accumulation of free fatty acids in the liver
coming from the AT and from their endogenous synthesis in the liver.a??

In the second poster presentation, PXL065 Phase 1 results demonstrated
that PXL065 was shown to be safe and well-tolerated with no adverse
events. Based on the pharmacokinetic (PK) results, modeling predicts
that a 15 mg dose of PXL065, a deuterium-stabilized R-stereoisomer of
pioglitazone, is expected to yield similar efficacy as 45 mg of the
parent drug, pioglitazone (ActosA®*) with an improved side
effect profile, including reduced weight gain and fluid retention.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »